CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Azithromycin TabletsWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)

Name (Synonyms) Correlation
drug1375 Low Dose (10 mg) Control Wiki 0.71
drug1726 PB1046 Wiki 0.71
drug1103 Hydroxychloroquine Sulfate Wiki 0.39

Correlated MeSH Terms (11)

Name (Synonyms) Correlation
D011654 Pulmonary Edema NIH 0.71
D000075902 Clinical Deterioration NIH 0.50
D011665 Pulmonary Valve Insufficiency NIH 0.29
D006333 Heart Failure NIH 0.27
D013577 Syndrome NIH 0.16
D007249 Inflammation NIH 0.14
D055371 Acute Lung Injury NIH 0.14
D012127 Respiratory Distress Syndrome, Newborn NIH 0.14
D012128 Respiratory Distress Syndrome, Adult NIH 0.12
D016638 Critical Illness NIH 0.10
D011014 Pneumonia NIH 0.04

Correlated HPO Terms (4)

Name (Synonyms) Correlation
HP:0100598 Pulmonary edema HPO 0.71
HP:0010444 Pulmonary insufficiency HPO 0.29
HP:0001635 Congestive heart failure HPO 0.27
HP:0002090 Pneumonia HPO 0.04

There are 2 clinical trials

Clinical Trials

1 Open, Multicentric, Non Randomized, Exploratory Clinical Trial to Assess the Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Acute Respiratory Syndrome (COVID-19) Caused by SARS-CoV-2 Virus

This is an exploratory study to evaluate the efficacy of hydroxychloroquine (400 mg BID on D1 and 400 mg/day on D2 to D5) and azithromycin (500 mg/ 5 days) to treat moderate to severe COVID-19 pneumonia.

NCT04329572 COVID-19 Drug: Hydroxychloroquine Sulfate Drug: Azithromycin Tablets

Primary Outcomes

Description: Evaluation of change from baseline. Kaplan-meier method will be used.

Measure: Evolution of acute respiratory syndrome, oxygen saturation hemodynamic stability

Time: 28 days

Secondary Outcomes

Description: Evaluation of change in viral load

Measure: Viral load

Time: Day 6

Description: Time for normalization of body temperature, respiratory rate and cough relief

Measure: Change in Clinical Condition

Time: 28 days

Description: Time to wean off oxygen supplementation and / or invasive / non-invasive ventilatory support;

Measure: Evolution of Acute Respiratory Syndrome

Time: 28 days

Description: Time to be discharged from hospital

Measure: Hospital discharge

Time: 28 days

Description: Evaluation of change in acute respiratory syndrome

Measure: Rate of mortality within 28-days

Time: 28 days

2 Open Label, Multicentric, Non Randomized, Exploratory Clinical Trial to Assess the Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Mild Acute Respiratory Syndrome (COVID-19) Caused by SARS-CoV-2 Virus

This is an exploratory study to evaluate the efficacy of hydroxychloroquine (400 mg BID on D1 and 400 mg/day on D2 to D7) and azithromycin (500 mg/ 5 days) to treat mild ambulatory COVID-19 patients.

NCT04348474 Covid-19 Drug: Hydroxychloroquine Sulfate Drug: Azithromycin Tablets

Primary Outcomes

Description: Ordinal scale (7 points ordinal scale that measures illness severity over time)

Measure: Change in Clinical Condition

Time: 28 days

Secondary Outcomes

Description: Number of patients that needed to be hospitalized

Measure: Hospitalization

Time: 28 days

Description: Time for normalization of body temperature

Measure: Change in Clinical Condition

Time: 28 days

Description: Time for normalization of of respiratory rate

Measure: Change in Clinical Condition

Time: 28 days

Description: Time for cough relief

Measure: Change in Clinical Condition

Time: 28 days

Description: Evaluation of change in acute respiratory syndrome

Measure: Rate of mortality within 28-days

Time: 28 days

Description: Subgroup analysis by comorbidities

Measure: Change in Clinical Condition related to comorbidity

Time: 28 days

No related HPO nodes (Using clinical trials)